Drug facts
Compounded semaglutide vs Ozempic
Quick answer
Ozempic is semaglutide approved for type 2 diabetes, dosed from 0.25 mg to a 2 mg maximum once weekly. A compounded vial may contain the same molecule, but it is not approved for anything, has no label and no trial of its own — and FDA has warned that some compounded semaglutide is a salt form, a different active ingredient from the one in Ozempic.
What Ozempic is approved for1
OZEMPIC is indicated:
- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
- to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Weight reduction is not among them; that is Wegovy’s approval, and the two are compared on Ozempic vs Wegovy. Many people use “Ozempic” as shorthand for semaglutide in general, which is why the comparison gets asked about a weight-loss vial at all.
One more thing the name now covers: Ozempic is also a tablet. Ozempic tablets, at 1.5, 4 and 9 mg once daily, are approved for type 2 diabetes on a label shared with Rybelsus — and that label says the two tablets are not interchangeable milligram for milligram.2 Nothing a compounding seller calls “oral semaglutide” is that product; see is there an oral semaglutide?
The doses are not Wegovy’s1
| Ozempic (diabetes) | Wegovy (weight) | |
|---|---|---|
| Start | 0.25 mg for 4 weeks | 0.25 mg for 4 weeks |
| Next | 0.5 mg | 0.5, then 1, then 1.7 mg |
| Maintenance | 0.5, 1 or 2 mg | 1.7 or 2.4 mg |
| Maximum | 2 mg | 7.2 mg (adults, weight reduction only) |
Every step is once weekly, and every increase waits at least four weeks. On Ozempic the dose rises only if more glucose control is needed; people with type 2 diabetes and chronic kidney disease maintain at 1 mg. The Wegovy column is on the dosage chart.3
This matters for a compounded prescription because it can follow either ladder. A “2 mg” compounded dose is Ozempic’s ceiling, and on Wegovy’s ladder it falls between the 1.7 mg and 2.4 mg steps; the number on its own does not tell you which schedule you are on.
What a compounded vial does not carry4
On the label — Wegovy / Ozempic
A known active ingredient. Ozempic contains semaglutide in a clear, colorless solution, with every inactive ingredient listed on its label.
In a compounded vial
FDA says some compounded semaglutide “may be the salt forms” — semaglutide sodium or acetate — which are different active ingredients, and it knows of no lawful basis for compounding with them. Ask the pharmacy what yours is.
On the label — Wegovy / Ozempic
A fixed strength. Ozempic pens hold 0.68, 1.34 or 2.68 mg per mL and deliver the dose they are set to.
In a compounded vial
A concentration the pharmacy chose. FDA has received adverse-event reports, some requiring hospitalization, that may be related to patients measuring the wrong dose of compounded semaglutide — see units and milligrams.
On the label — Wegovy / Ozempic
Approval, and trials. Reviewed and approved for three stated uses in type 2 diabetes.
In a compounded vial
Not approved for any use, and no trial of the preparation. The full comparison with the weight product is on compounded semaglutide vs Wegovy.
If you have type 2 diabetes
Semaglutide lowers blood glucose, and combining it with insulin or a sulfonylurea raises the risk of low blood sugar — the label’s interaction section, covered in semaglutide and other medicines. A diabetes regimen is usually adjusted around semaglutide, and that is the prescriber’s job whichever product is in the syringe. If you are buying through a weight-loss program, its intake form is not a diabetes consultation; the person managing your diabetes should know exactly what you are taking and at what concentration.
Switching from Ozempic
On paper the milligram dose carries over, if the vial contains the same active ingredient. In practice two things change. The dose has to be measured by volume at the vial’s own concentration, where the pen did it for you. And a compounded vial carries a beyond-use date and a 28-day limit once opened, where an Ozempic pen can be kept 56 days after first use — see how long compounded semaglutide lasts. Moving between products is covered in switching sellers, or switching molecules.
Questions
- Is compounded semaglutide the same as Ozempic?
- Not the same product. Ozempic is FDA-approved semaglutide for type 2 diabetes; a compounded preparation is not approved for any use, has no label or trial of its own, and FDA has warned that some compounded semaglutide is a salt form — a different active ingredient from the one in Ozempic.
- What is the difference between compounded semaglutide and Ozempic?
- Approval, strength and certainty about the ingredient. Ozempic is approved for three uses in type 2 diabetes, comes in pens of fixed concentration and is dosed to a 2 mg maximum. A compounded vial's concentration and beyond-use date are set by the pharmacy, and its active ingredient has not been reviewed by FDA.
- Is Ozempic approved for weight loss?
- No. Ozempic is approved for glycemic control in adults with type 2 diabetes, and to reduce cardiovascular and kidney risks in type 2 diabetes. The semaglutide product approved for weight reduction is Wegovy.
- What is the maximum dose of Ozempic compared with Wegovy?
- Ozempic's maximum is 2 mg once weekly. Wegovy's maintenance dose is 1.7 or 2.4 mg, and adults using it for weight reduction may go to a 7.2 mg maximum after at least four weeks at 2.4 mg.
- Is there an Ozempic pill?
- Yes. Ozempic tablets, at 1.5, 4 and 9 mg once daily, are approved for type 2 diabetes on a label shared with Rybelsus, and the two tablets are not interchangeable milligram for milligram. What compounding sellers market as oral semaglutide is not that product.
Sources
- FDA prescribing information for OZEMPIC (semaglutide) injection, sections 1, 2, 11 and 16, revision 5/2026 DailyMed
- FDA prescribing information for RYBELSUS and OZEMPIC (semaglutide) tablets, revision 1/2026 DailyMed
- FDA prescribing information for WEGOVY (semaglutide), section 2.2, revision 6/2026 DailyMed
- FDA, 'FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss', content current as of 09/01/2026 FDA